Lilly/BioMS Forge Ahead With MS Drug After Phase II/III Interim Look
This article was originally published in The Pink Sheet Daily
Executive Summary
Dirucotide gets positive nod from DSMB; Lilly to pay $10 million milestone to BioMS.
You may also be interested in...
Lilly Inks Deal With BioMS For Phase III Multiple Sclerosis Compound
Collaboration valued at $497 million plus royalties aims to develop, commercialize synthetic peptide MBP8298, Lilly tells “The Pink Sheet” DAILY.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.